MedTrace Logo

Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children

NCT04569357 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 363

Last updated 2024-08-01

Study results available
· View outcomes & findings →

Summary

Purpose of the study:

• evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

Prospekta

Oral administration.

DRUG

Placebo

Oral administration.

Sponsors & Collaborators

  • Materia Medica Holding

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2022-02-18
Completion
2022-02-18

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569357 on ClinicalTrials.gov